Aileron Therapeutics to Speak at Two Investor Conferences

28 June 2024

AUSTIN, Texas, May 6, 2024 -- Aileron Therapeutics, Inc. (“Aileron”) (NASDAQ: ALRN), a biopharmaceutical company dedicated to creating innovative medications for orphan pulmonary and fibrosis conditions, has announced that its President and CEO, Brian Windsor, Ph.D., will be presenting at two upcoming investor conferences. 

The first presentation will take place at the Citizens JMP Life Sciences Conference on Monday, May 13, 2024, at 12:00 p.m. EDT. This session will feature a company presentation by Dr. Windsor. The second event, the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ, will occur on Monday, May 20, 2024, at 5:00 p.m. EDT and will be conducted in a fireside chat format. 

Aileron Therapeutics is at the forefront of developing unique, first-in-class treatments for severe medical conditions in the pulmonary and fibrosis fields. Their leading product, LTI-03, is an innovative synthetic peptide designed to enhance alveolar epithelial cell survival while simultaneously inhibiting profibrotic signaling. LTI-03 is currently undergoing a Phase 1b clinical trial aimed at treating idiopathic pulmonary fibrosis, with results from Cohort 2 anticipated in the third quarter of this year.

Additionally, Aileron is developing LTI-01, a proenzyme that has successfully completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions. Notably, LTI-01 has been granted Orphan Drug Designation in both the United States and the European Union, as well as Fast Track Designation in the United States.

Aileron's commitment to addressing unmet medical needs through novel therapeutic approaches places them at the cutting edge of biopharmaceutical innovation. Their progress in clinical trials and strategic presentations at major investor conferences underscore the company’s pivotal role in advancing treatments for challenging pulmonary and fibrosis conditions.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!